Pharmaceutical

Love Pharma Inc. ("LOVE" and or "the Company") (CSE:LUV)(FSE:G1Q0), announces it has completed a first closing of a non-brokered private placement. The Company accepted subscriptions for 16,550,000 units at a price of $0.02 per unit, for gross proceeds of $331,000. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share at $0.05 for a period of two years from the date of closing, subject to the option of the Company to accelerate the expiry date in the event that its shares trade at $0.15 or more for 10 consecutive days

The Company paid $9,050 in cash and issued 400,000 broker warrants on the same terms as noted above, to qualified finders. Securities issued pursuant to this tranche are subject to trading restrictions until August 6, 2022.

Proceeds will be used for working capital and to review possible acquisitions.

About Love Pharma Inc.

With a focus on the global sexual Health and Wellness markets, Love Pharma Inc. (CSE: LUV) (FSE: G1Q0) was founded in 2020, with a mission to bring to market innovative products that enhance sexual health and wellness while providing an improved quality of life. Love Pharma holds exclusive licenses to produce market, package, sell, and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America.

For further information, please contact:

Investor Relations
Telephone: 1 (604) 343-2977
E-mail: investors@love-pharma.com
www.love-pharma.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "predicts", "intends", "targets", "aims", "anticipates", "may" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions, risks relating to epidemics or pandemics such as COVID-19, including the impact of COVID-19 on the Company's business, financial condition and results of operations, lack of investor demand for Bitcoin and/or Bitcoin futures exchange traded funds, and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.

SOURCE: Love Pharma Inc.



View source version on accesswire.com:
https://www.accesswire.com/696213/Love-Pharma-Inc-Announces-First-Closing-of-Financing

News Provided by ACCESSWIRE via QuoteMedia

LUV:CNX
love pharma

Love Pharma

Overview

Attitudes about sexual wellness are changing, and the market is directly reflecting these changes. Sexual wellness is a general term that refers to the physical, mental and social well-being of an individual. This broad market is made up of any product related to sexual wellness, such as supplements, contraceptives, lingerie, and other holistic products.

A report conducted by KBV Research estimates that the global sexual wellness market size will reach US$125.1 billion by 2026, with the potential for a 12.4 percent CAGR during this period. This steady growth has been driven by a renewed interest in sexual discovery, rising prevalence of sexually transmitted diseases, and the broader shift to ecommerce.

Love Pharma (CSE:LUV) creates innovative science-driven products to cater to the ever-evolving space of sexual health and wellness. It aims to deliver breakthrough products that enhance the everyday life of the end-user by increasing intimacy and pleasure.

The company is on a mission to offer new and trustworthy products that make use of “new age" pharmaceuticals that are backed by thorough scientific research. Love Pharma will launch with products that focus on nutraceuticals, which are pharmaceutical alternatives that have naturally occurring benefits, such as CBD and THC. It will launch with two products: Bloom and Auralief. Additional products are already under development.

Bloom is a CBD and/or THC-infused arousal gel that is intended for female pleasure. According to the KBV report, women are the fastest-growing segment of the sexual wellness market. They attribute this trend to the increase in working women along with more availability of sex education. While female contraceptives will make up a large part of this growing segment, other products for women may perform well. The Bloom arousal gel does not have any psychoactive effects and is designed to enhance blood flow, creating physical stimulation with the ultimate goal of increasing pleasure.

In May 2021, Love Pharma partnered with Potent Ventures (OTCMKTS: POTVF) to help launch Love Pharma's flagship projects in the United States. The United States sexual wellness market is expected to reach US$15.9 billion by 2027, making this a key partnership for the success of Love Pharma's initial product launch.

Company Highlights

  • Love Pharma specializes in sexual health and wellness by distributing products infused with CBD and THC directly to consumers. It holds exclusive licenses to produce, market, package, sell and distribute these patent-protected products throughout North America, the United Kingdom and Europe.
  • The company is investing in creating sustainable long-term sales through strategic distributor partnerships
  • The launch products, Bloom and Auralief, are licensed for retail sales, creating an immediate opportunity for revenue
  • Love Pharma has already planned domestic and international expansion
  • The management team has an established history of success with cannabis and pharmaceutical products
  • The company plans to create research-backed products that make use of psychedelics and nutraceuticals
  • Once the company is publicly listed, plans are already in place to rapidly distribute products and quickly generate revenue
  • Love Pharma completed the acquisition of MicroDoz Theraphy Inc.

Key Projects

Bloom

This topical gel is infused with CBD and/or THC with the purpose of increasing blood flow and sensitivity. The product is applied to the vaginal area and quickly generates blood flow, which is followed by physical stimulation. The company reports having clinical success with increasing the speed to orgasm and the number of orgasms, both of which are important when discussing physical intimacy.

The initial version of this product that launches will only contain CBD. Love Pharma has a medical advisor on the product creation side of the company who indicates that CBD enhances the nerve receptor interaction and blood flow, both of which create more pleasure. Future versions of this product will contain THC.

Auralief

Auralief is designed to provide relaxation and pain relief. This product is a mucoadhesive strip that is applied under the tongue, similar to popular breath-freshening strips. This creates constant contact with this soft membrane that will allow for maximum absorption of the CBD within the product. Auralief is backed by a recent human trial that showed a 30% increase in efficacy and speed to performance of CBD and THC.

Management Team

Zachary Stadnyk – Director and Chief Executive Office

Zachary Stadnyk is a corporate finance and advisory professional specializing in taking companies public in emerging markets. Stadnyk served as the head of corporate finance for The Supreme Cannabis Company from 2014-1018 which raised over $300,000,000 and was later acquired by Canopy growth in 2021 for $435M. Stadnyk was the founder, director and chief executive officer of DC Acquisition Corp, a Capital Pool Company (“CPC") that raised an initial $3,000,000 on its IPO and listed on the TSX.V. The issuer completed its qualifying transaction with Kiaro Brands, a leading cannabis retailer, in October 2020, which is targeting doing $50,000,000 in revenue in fiscal 2022. Stadnyk also serves on the board of Health Logic Interactive (CHIP – TSXV) an early-stage medical device company.

Tatiana Kovaleva – Chief Financial Officer

Tatiana Kovaleva is a Vancouver-based finance executive with international and trans-border expertise and credentials as a CPA. Kovaleva has extensive experience in capital markets, where for over twenty years she served in multiple capacities, including chief financial officer for publicly traded companies such as M Pharmaceutical Inc. and 360 Blockchain Inc

Kovaleva utilized her specialized executive management experience in public company financial planning and demonstrated a successful track record with timely and accurate financial forecasting, budgeting, reporting and consolidations, IFRS and GAAP accounting.

Joshua Maurice – Chief Operating Officer

Following four years at Callitas Therapeutics-during which time he quickly rose through the ranks from Director of Sales & Marketing to VP of Sales & Business Development and then to President-Mr. Maurice comes to Love Pharma with 20 years of experience in consumer goods with a focus on the development of over-the-counter drug and nutraceuticals, including efficacy, clinical research, branding, marketing, advertising, and global retail distribution.

Douglas Taylor – Director

Douglas Taylor has over 30 years of extensive experience in managing projects, services and facilities in the public sector. His previous work included community engagement, strategic planning, business planning and implementation for a wide range of recreational facilities and services. Implementation encompassed budgeting, financial planning, auditing and managing human resources. Taylor's degree includes two levels of managerial accounting. He has served on the Glenbriar Board as CEO for three years and as president for the past two and a half years.

Mark Tommasi – Director

Mark Tommasi has worked as a senior officer, director, financier and consultant with over 25 years of experience in corporate development, equity, private equity and venture capital financing, IPO's and private placements, marketing, investor relations and board and committee activities for numerous public and private companies (agriculture, technology, junior exploration, and oil and gas) in both the United States and Canada. Tommasi has been noted for his ability to help young companies get to the next level.

Love Pharma Inc. Announces Second Closing of Financing

Love Pharma Inc. Announces Second Closing of Financing

Love Pharma Inc. ("LOVE" and or "the Company") (CSE:LUV)(FSE:G1Q0), announces it has completed a second closing of its previously announced non-brokered private placement. The Company accepted subscriptions for 50,735,771 units at a price of $0.011 per unit, for gross proceeds of $558,093.50. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share at $0.05 for a period of two years from the date of closing, subject to the option of the Company to accelerate the expiry date in the event that its shares trade at $0.15 or more for 10 consecutive days

The Company paid $32,655.48 in cash and issued 2,968,680 broker warrants on the same terms as noted above, to qualified finders. Securities issued pursuant to this tranche are subject to trading restrictions until October 30, 2022.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Love Pharma Announces Closing of MicroDoz Therapy Acquisition

Love Pharma Announces Closing of MicroDoz Therapy Acquisition

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Love Pharma Co. ("LOVE" and or "The Company") (CSE:LUV)(FSE:G1Q0), is pleased to announce that it has completed its acquisition (the "Acquisition") of MicroDoz Theraphy Inc. ("MicroDoz") (as originally disclosed in a press release on November 23, 2021 and as updated on March 3, 2022

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Love Pharma Inc. Announces Closing of Financing

Love Pharma Inc. Announces Closing of Financing

Love Pharma Inc. ("LOVE" and or "the Company") (CSE:LUV)(FSE:G1Q0), announces it has completed the second tranche of a non-brokered private placement. The Company accepted subscriptions for 2,375,000 units at a price of $0.02 per unit, for gross proceeds of $47,500. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share at $0.05 for a period of two years from the date of closing, subject to the option of the Company to accelerate the expiry date in the event that its shares trade at $0.15 or more for 10 consecutive days

The Company paid $3,800 in cash and issued 190,000 broker warrants on the same terms as noted above, to qualified finders. Securities issued pursuant to this tranche are subject to trading restrictions until September 7, 2022.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Love Pharma Updates Microdoz Proposed Acquisition with Global Leader in Psychedelic Research

Love Pharma Updates Microdoz Proposed Acquisition with Global Leader in Psychedelic Research

Love Pharma Co. ("LOVE" and or "The Company") (CSE:LUV)(FSE:G1Q0), the Company is pleased to announce updated details on the proposed Microdoz Therapy acquisition (originally announced in a press release on November 23, 2021), whereby Microdoz has engaged exclusively with researchers at Johns Hopkins University, the top psychedelic center in the World, located in the eastern United States, to conduct a landmark study into the potential of psilocybin assisted treatment of cannabis use disorder. The company looks forward to working with the university and research experts on the study and, ultimately, licensing and commercializing the intellectual property developed by the landmark study

"This is a significant opportunity to develop treatments with efficacy for people who are today subject to Cannabis Use Disorder and those who will become subject to it in the future," said Mr. Zach Stadnyk, Love Pharma CEO. "The U.S. cannabis industry is forecast to surpass $41 billion by 20252, and the National Institute on Drug Abuse has released research suggesting 9% - 30% of people using cannabis may develop cannabis use disorder3, so we see an opportunity where Love can help people facing this disorder along with our research partners, while at the same time developing a lucrative market for treatment that will benefit our shareholders."

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Love Pharma's Acquisition Will Offer Exclusive Partnership and License with World Renowned University to Conduct Landmark Psilocybin Study

Love Pharma's Acquisition Will Offer Exclusive Partnership and License with World Renowned University to Conduct Landmark Psilocybin Study

Love Pharma Inc. (CSE: LUV) (FSE: G1Q0) continues to prioritize the necessity for clinical validation as a vital step in bringing its products to market.  The Vancouver, Canada-based company, which operates as a specialized health and wellness company that licenses and distributes psychedelic and cannabis-infused products, has established a practice of offering proven products with clinical data, user studies, and scientific research to support its claims.  It's a practice that gives Love Pharma a distinct market advantage over many of its competitors.  And now, Love Pharma is set to broaden that advantage with its recent announcement that the company has signed a Letter of Intent to acquire MicroDoz Therapy, Inc.

The benefit of this acquisition to Love Pharma, its shareholders and worldwide consumers is that the company gains MicroDoz's exclusive partnership with a world-renowned university to conduct a landmark study into the efficacy of psilocybin assisted treatment of cannabis use disorder.  Love Pharma can leverage this relationship to further expand its product lineup, strengthen its clinical validation program, and add to its comprehensive portfolio of intellectual property.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology

Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion

Potential to address the full spectrum of critical needs in the underserved sickle cell community

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis

  • Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with endometriosis, and a loss of mean bone mineral density of less than 1% from baseline through one year of treatment
  • Myovant and Pfizer will continue to jointly commercialize MYFEMBREE, with product available immediately
  • Myovant to host conference call and webcast on Monday, August 8, 2022, at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time

Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved MYFEMBREE ® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as a one-pill, once-a-day therapy for the management of moderate to severe pain associated with endometriosis in pre-menopausal women, with a treatment duration of up to 24 months. The approval is supported by one-year efficacy and safety data, including 24-week data from the Phase 3 SPIRIT 1 and SPIRIT 2 trials, which were published in The Lancet and the first 28 weeks of an open-label extension study for eligible women who completed either SPIRIT 1 or SPIRIT 2. MYFEMBREE also is approved for heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Myovant and Pfizer will continue to jointly commercialize MYFEMBREE in the U.S. and product is available immediately.

"Endometriosis is a painful, chronic disease with limited therapies to manage symptoms," said Juan Camilo Arjona Ferreira, M.D., Chief Medical Officer of Myovant Sciences, Inc. "The new MYFEMBREE indication helps advance our mission to redefine care for women by helping address a disease with high unmet need, giving women and physicians a new meaningful treatment option to manage moderate to severe pain associated with endometriosis."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Jamieson Wellness Inc. Reports Second Quarter 2022 Financial Results

Company Increases Fiscal 2022 Guidance and Raises Second Quarter Dividend

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX: JWEL) today reported financial results for its second quarter ended June 30, 2022. All amounts are expressed in Canadian dollars. Certain metrics, including those expressed on an adjusted basis, are non-IFRS and other financial measures. See "Non-IFRS and Other Financial Measures" below.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

LYNPARZA® Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission (EC) has approved LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA 1/2 mutations (g BRCA m), who have human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® Plus LENVIMA® Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the Phase 3 LEAP-002 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, versus LENVIMA monotherapy did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) as a first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC). There were trends toward improvement in OS and PFS for patients who received KEYTRUDA plus LENVIMA versus LENVIMA monotherapy; however, these results did not meet statistical significance per the pre-specified statistical plan. The median OS of the LENVIMA monotherapy arm in LEAP-002 was longer than that observed in previously reported clinical trials evaluating LENVIMA monotherapy in uHCC. The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination. Merck and Eisai plan to present these data at an upcoming medical conference.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220803005211/en/

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Phase 3 KEYNOTE-921 trial evaluating KEYTRUDA in combination with chemotherapy (docetaxel) compared to chemotherapy alone did not meet its dual primary endpoints of overall survival (OS) and radiographic progression-free survival (rPFS) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). In the study, there were modest trends toward an improvement in both OS and rPFS for patients who received KEYTRUDA plus chemotherapy compared with chemotherapy alone; however, these results did not meet statistical significance per the pre-specified statistical plan. The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies. Results will be presented at an upcoming medical meeting.

"Results from this study serve as an important reminder that metastatic prostate cancer remains very difficult to treat, and more research is needed. We will continue to advance our clinical development program to evaluate KEYTRUDA-based combinations and novel candidates for patients with this disease," said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. "We are grateful to the patients and investigators for their participation in this study."

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×